2024
Single-Cell Analysis Reveals Novel Immune Perturbations in Fibrotic Hypersensitivity Pneumonitis.
Zhao A, Unterman A, Abu Hussein N, Sharma P, Nikola F, Flint J, Yan X, Adams T, Justet A, Sumida T, Zhao J, Schupp J, Raredon M, Ahangari F, Deluliis G, Zhang Y, Buendia-Roldan I, Adegunsoye A, Sperling A, Prasse A, Ryu C, Herzog E, Selman M, Pardo A, Kaminski N. Single-Cell Analysis Reveals Novel Immune Perturbations in Fibrotic Hypersensitivity Pneumonitis. American Journal Of Respiratory And Critical Care Medicine 2024, 210: 1252-1266. PMID: 38924775, PMCID: PMC11568434, DOI: 10.1164/rccm.202401-0078oc.Peer-Reviewed Original ResearchFibrotic hypersensitivity pneumonitisIdiopathic pulmonary fibrosisPeripheral blood mononuclear cellsBronchoalveolar lavage cellsBlood mononuclear cellsClassical monocytesHypersensitivity pneumonitisPulmonary fibrosisT cellsImmune perturbationsLavage cellsMononuclear cellsCD8+ T cellsCytotoxic T cellsInterstitial lung diseaseHypersensitivity pneumonitis patientsCytotoxic CD4Immune aberrationsPneumonic patientsPneumonitisLung diseaseHealthy controlsImmune mechanismsPatient cellsSingle-cell transcriptomics
2023
Dose-Volume Predictors of Radiation Pneumonitis After Thoracic Hypofractionated Radiation Therapy
Sasse A, Oh P, Saeed N, Yang D, Hayman T, Knowlton C, Peters G, Campbell A, Laird J, Housri N, Park H. Dose-Volume Predictors of Radiation Pneumonitis After Thoracic Hypofractionated Radiation Therapy. Practical Radiation Oncology 2023, 14: e97-e104. PMID: 37984711, DOI: 10.1016/j.prro.2023.11.006.Peer-Reviewed Original ResearchMean lung doseHypofractionated radiation therapyRisk of gradeRadiation pneumonitisLung V20Lung V5Dose-volume predictorsDosimetric risk factorsLogistic regression analysisGrade 5 casesSingle healthcare systemPrimary endpointDose regimensMultivariable analysisLung doseThoracic tumorsDosimetric variablesRisk factorsPneumonitisRadiation therapyCommon treatmentClinical practicePatientsSignificant associationPotential predictorsHeterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept
Aminu M, Daver N, Godoy M, Shroff G, Wu C, Torre-Sada L, Goizueta A, Shannon V, Faiz S, Altan M, Garcia-Manero G, Kantarjian H, Ravandi-Kashani F, Kadia T, Konopleva M, DiNardo C, Pierce S, Naing A, Kim S, Kontoyiannis D, Khawaja F, Chung C, Wu J, Sheshadri A. Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept. Frontiers In Immunology 2023, 14: 1249511. PMID: 37841255, PMCID: PMC10570510, DOI: 10.3389/fimmu.2023.1249511.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsGround-glass opacitiesBlood biomarkersImmune checkpoint inhibitor pneumonitisCheckpoint inhibitor pneumonitisAcute myeloid leukemiaPost-test probabilityCheckpoint inhibitorsMyeloid leukemiaCT patternsLung inflammationPneumonitisInfected lungsRelevant blood biomarkersDiagnostic valueLung parenchymaPneumoniaCT imagesBloodBiomarkersPatientsHabitat imagesBlood modelDetection of pneumoniaLeukemiaCardiothoracic complications of immune checkpoint inhibitors
Gosangi B, Wang Y, Rubinowitz A, Kwan J, Traube L, Gange C, Bader A. Cardiothoracic complications of immune checkpoint inhibitors. Clinical Imaging 2023, 102: 98-108. PMID: 37659356, DOI: 10.1016/j.clinimag.2023.08.001.Peer-Reviewed Educational MaterialsConceptsImmune checkpoint inhibitorsICI therapyCheckpoint inhibitorsOverall survivalTumor responseAdverse effectsDevelopment of irAEsNovel adverse effectsImproved overall survivalOverall patient outcomesICI administrationHematologic malignanciesPatient outcomesSolid tumorsIrAEsCancer treatmentGreater mortalityComplicationsTherapySurvivalInhibitorsMyocarditisPneumonitisPatientsMalignancySarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature
Soto F, Torre-Sada L, Mott F, Kim S, Nurieva R, Nagarajan P, Guo M, Shannon V, Faiz S, Casal R, Altan M, Lin J, Sheshadri A. Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature. Journal Of Immunotherapy And Precision Oncology 2023, 6: 111-116. PMID: 37214206, PMCID: PMC10195014, DOI: 10.36401/jipo-22-30.Peer-Reviewed Original ResearchImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyInhibitor therapyPulmonary toxicityEosinophilic asthmaAirway diseaseImmune related adverse eventsPD-1 inhibitor pembrolizumabSevere eosinophilic asthmaRelated adverse eventsICI therapyInhibitor pembrolizumabPD-1Benign courseTreatment cessationFatal complicationCase reportAdverse eventsSarcoidosisTherapyPneumonitisAirwayPatientsToxicityAsthma
2022
Unilateral Pneumonitis and Hydropneumothorax Following Pembrolizumab
Sanchez A, Kahn P, Minerowicz C, Kluger H. Unilateral Pneumonitis and Hydropneumothorax Following Pembrolizumab. Journal Of Brown Hospital Medicine 2022, 2: 39747. PMID: 40046551, PMCID: PMC11878863, DOI: 10.56305/001c.39747.Peer-Reviewed Case Reports and Technical NotesCheckpoint inhibitor pneumonitisTransbronchial biopsy resultsBronchoalveolar lavage fluidProgressive dyspneaDry coughPembrolizumab monotherapyLavage fluidRadiographic findingsBiopsy resultsMetastatic melanomaPleural fluidPneumonitisHydropneumothoraxPembrolizumabDyspneaMonotherapyCoughPneumoniaMelanomaSymptomsInfectionWeeks
2020
Pulmonary Complications of Immunotherapy
Bade BC, Possick JD. Pulmonary Complications of Immunotherapy. Clinics In Chest Medicine 2020, 41: 295-305. PMID: 32402364, DOI: 10.1016/j.ccm.2020.02.012.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLung cancerImmune checkpoint inhibitor therapyImmune-related adverse eventsTreatment-limiting complicationsCheckpoint inhibitor therapyFurther prospective investigationMetastatic lung cancerFavorable safety profileTreatment of patientsPulmonary complicationsAdverse eventsClinical vigilanceInhibitor therapySignificant morbiditySafety profileProspective InvestigationCurrent guidelinesMortality riskImmunotherapyComplicationsPatientsCancerPneumonitisMorbidityChemotherapy
2019
Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor–related Pneumonitis. An Official American Thoracic Society Research Statement
Sears CR, Peikert T, Possick JD, Naidoo J, Nishino M, Patel SP, Camus P, Gaga M, Garon EB, Gould MK, Limper AH, Montgrain PR, Travis WD, Rivera MP. Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor–related Pneumonitis. An Official American Thoracic Society Research Statement. American Journal Of Respiratory And Critical Care Medicine 2019, 200: e31-e43. PMID: 31518182, PMCID: PMC6775885, DOI: 10.1164/rccm.201906-1202st.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsImmune checkpoint inhibitorsICI-pneumonitisCheckpoint inhibitorsOfficial American Thoracic Society Research StatementUse of ICIsLife-threatening pneumonitisUnique adverse eventsBiological mechanismsAdverse eventsRadiologic featuresRadiologic presentationCancer careBiologic mechanismsResearch prioritiesBasic biological mechanismsMultidisciplinary groupPneumonitisClinical researchersDiagnosisInhibitorsPrecipitous increaseTherapyAvailable dataCare
2018
Is It Idiopathic Pulmonary Fibrosis or Not?
Salvatore M, Ishikawa G, Padilla M. Is It Idiopathic Pulmonary Fibrosis or Not? The Journal Of The American Board Of Family Medicine 2018, 31: 151-162. PMID: 29330249, DOI: 10.3122/jabfm.2018.01.170288.Peer-Reviewed Original ResearchConceptsUsual interstitial pneumonitisPulmonary fibrosisInterstitial pneumonitisCorrect diagnosisAccurate diagnosisUIP/IPFChronic hypersensitivity pneumonitisIdiopathic pulmonary fibrosisNonspecific interstitial pneumonitisPulmonary fibrotic diseasesAmerican Thoracic SocietyAntifibrotic medicationsFibrotic sarcoidosisMean life expectancySerologic testingWorse prognosisCareful historyHypersensitivity pneumonitisThoracic SocietyFibrotic pathwaysInvasive proceduresClinician's abilityFibrotic diseasesPneumonitisFibrosis
2017
Th1/17 Hybrid CD4+ Cells Are Expanded in Bronchial Alveolar Lavage Fluid from Leukemia Patients with Checkpoint Inhibitor-Induced Pneumonitis
Kim S, Shannon V, Sheshadri A, Kantarjian H, Garcia-Manero G, Im J, Ravandi F, Naing A, Sharma P, Kontoyiannis D, Futreal A, Daver N. Th1/17 Hybrid CD4+ Cells Are Expanded in Bronchial Alveolar Lavage Fluid from Leukemia Patients with Checkpoint Inhibitor-Induced Pneumonitis. Clinical Lymphoma Myeloma & Leukemia 2017, 17: s10. DOI: 10.1016/j.clml.2017.09.037.Peer-Reviewed Original ResearchFatal case of cutaneous‐sparing orolaryngeal zoster in a renal transplant recipient
Helou E, Grant M, Landry M, Wu X, Morrow JS, Malinis MF. Fatal case of cutaneous‐sparing orolaryngeal zoster in a renal transplant recipient. Transplant Infectious Disease 2017, 19 PMID: 28401625, DOI: 10.1111/tid.12704.Peer-Reviewed Case Reports and Technical NotesConceptsTransplant recipientsHerpes zosterSolid organ transplant recipientsCTLA-4 inhibitorsKidney transplant recipientsRenal transplant recipientsOrgan transplant recipientsAcute rejectionSOT recipientsMucosal lesionsMeningo-encephalitisPoor outcomeFatal casesHerpesvirus infectionSignificant causeRecipientsZosterPneumonitisMorbidityPatientsLesionsInfectionMortalityCases
2016
Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors.
Gettinger S, Zhang X, Homer R, Possick J, Wurtz A, Goldberg S, Chiang A, Herbst R, Rubinowitz A. Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors. Journal Of Clinical Oncology 2016, 34: 9030-9030. DOI: 10.1200/jco.2016.34.15_suppl.9030.Peer-Reviewed Original Research
2013
Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis
Gartrell B, Ying J, Sivendran S, Boucher K, Choueiri T, Sonpavde G, Oh W, Agarwal N, Galsky M. Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Targeted Oncology 2013, 9: 195-204. PMID: 23852656, PMCID: PMC4744485, DOI: 10.1007/s11523-013-0289-2.Peer-Reviewed Original ResearchConceptsMammalian target of rapamycin inhibitorsMammalian target of rapamycinPulmonary adverse eventsIncidence rate ratiosMTOR inhibitorsIncidence rateGrade pneumonitisAdverse eventsIncidence of grade 3Patients treated with mTOR inhibitorsClinical trials of mTOR inhibitorsMeta-analysisSystematic reviewTargeted cancer therapyAdverse event dataPulmonary complicationsASCO abstractsRate ratiosSolid tumorsGrade 3Target of rapamycinPneumonitisClinical trialsCancer therapyRelative to controls
2012
Chronic inflammation and lung fibrosis: pleotropic syndromes but limited distinct phenotypes
Gifford AH, Matsuoka M, Ghoda LY, Homer RJ, Enelow RI. Chronic inflammation and lung fibrosis: pleotropic syndromes but limited distinct phenotypes. Mucosal Immunology 2012, 5: 480-484. PMID: 22806097, DOI: 10.1038/mi.2012.68.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisPulmonary fibrosisClinical entityHypersensitivity pneumonitisLung diseaseLung fibrosisDifferent clinical presentationsDistinct phenotypesPostinflammatory fibrosisClinical presentationRheumatoid arthritisChronic inflammationClinical syndromeTherapeutic responseClinical diseaseMultiple potential reasonsFibrosisFibrotic phenotypeExperimental modelDiseaseSyndromeMatrix depositionPhenotypePhenotypic distinctionPneumonitis
1992
Serologic evidence of active Epstein-barr virus infection in epstein-barr virus-associated lymphoproliferative disorders of children with acquired immunodeficiency syndrome
Katz B, Berkman A, Shapiro E. Serologic evidence of active Epstein-barr virus infection in epstein-barr virus-associated lymphoproliferative disorders of children with acquired immunodeficiency syndrome. The Journal Of Pediatrics 1992, 120: 228-232. PMID: 1310507, DOI: 10.1016/s0022-3476(05)80432-9.Peer-Reviewed Original ResearchConceptsEpstein-Barr virusLymphocytic interstitial pneumonitisNon-Hodgkin lymphomaCase patientsImmunodeficiency syndromeControl patientsSerologic evidenceEBV infectionInterstitial pneumonitisVirus infectionIndex patientsEpstein-Barr virus-associated lymphoproliferative disorderActive Epstein-Barr virus infectionEpstein-Barr virus infectionHuman immunodeficiency virus (HIV) infectionIndex case patientsActive EBV infectionImmunodeficiency virus infectionCase-control studySpecimens of tissueVirologic evidenceLymphoproliferative disordersSerologic profilePatientsPneumonitis
1991
Relation between HIV-1 syncytium inhibition antibodies and clinical outcome in children
Brenner TJ, Dahl KE, Miller G, Andiman W, Andiman WA, Olson B, Miller G, Andiman W, Miller G. Relation between HIV-1 syncytium inhibition antibodies and clinical outcome in children. The Lancet 1991, 337: 1001-1005. PMID: 1673167, DOI: 10.1016/0140-6736(91)92660-t.Peer-Reviewed Original ResearchConceptsLymphocytic interstitial pneumonitisOpportunistic infectionsClinical outcomesSyncytium formationCD4 receptorHIV-1-infected mothersWestern blotHIV-1 infected cellsInterstitial pneumonitisInhibition antibodiesHIV-1Giant cellsIndicator cellsAntibodiesInfected cellsTitresChildrenCell linesCell spreadSerumReceptorsOutcomesVirusCellsPneumonitis
1984
Busulfan and total body irradiation as antihematopoietic stem cell agents in the preparation of patients with congenital bone marrow disorders for allogenic bone marrow transplantation.
Parkman R, Rappeport JM, Hellman S, Lipton J, Smith B, Geha R, Nathan DG. Busulfan and total body irradiation as antihematopoietic stem cell agents in the preparation of patients with congenital bone marrow disorders for allogenic bone marrow transplantation. Blood 1984, 64: 852-7. PMID: 6383499, DOI: 10.1182/blood.v64.4.852.bloodjournal644852.Peer-Reviewed Original ResearchConceptsTotal body irradiationBone marrow transplantationBone marrow disordersBody irradiationPreparation of patientsMarrow transplantationMarrow disordersInterstitial pneumonitisAllogeneic bone marrow transplantationAllogenic bone marrow transplantationIdiopathic interstitial pneumonitisCell agentsPreparatory regimenBusulfanPatientsHematopoietic stem cellsTransplantationTransplantPneumonitisDisordersHematopoietic ablationStem cellsRegimenRegimensAgentsBusulfan and Total Body Irradiation as Antihematopoietic Stem Cell Agents in the Preparation of Patients With Congenital Bone Marrow Disorders for Allogeneic Bone Marrow Transplantation
Parkman R, Rappeport J, Hellman S, Lipton J, Smith B, Geha R, Nathan D. Busulfan and Total Body Irradiation as Antihematopoietic Stem Cell Agents in the Preparation of Patients With Congenital Bone Marrow Disorders for Allogeneic Bone Marrow Transplantation. Blood 1984, 64: 852-857. DOI: 10.1182/blood.v64.4.852.852.Peer-Reviewed Original ResearchTotal body irradiationBone marrow transplantationBone marrow disordersAllogeneic bone marrow transplantationBody irradiationPreparation of patientsMarrow transplantationMarrow disordersInterstitial pneumonitisIdiopathic interstitial pneumonitisCell agentsPreparatory regimenBusulfanPatientsHematopoietic stem cellsTransplantationTransplantPneumonitisDisordersHematopoietic ablationStem cellsRegimenRegimensAgents
1969
Aspergillus Lobar Pneumonia
Young R, Vogel C, DeVita V. Aspergillus Lobar Pneumonia. JAMA 1969, 208: 1156-1162. PMID: 5818713, DOI: 10.1001/jama.1969.03160070034008.Peer-Reviewed Original ResearchConceptsPleuritic chest painConsistent with pathological findingsLobar pneumoniaChest painPulmonary embolismFungal pneumoniaLobar consolidationVascular invasionHematopoietic malignanciesAspergillus fumigatusClinical symptomsPathological findingsPneumoniaBacterial agentsPatientsAspergillosisHemoptysisChemotherapyPneumonitisCorticosteroidsLeukopeniaMalignancyEmbolizationHemorrhagePain
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply